RYTM
RHYTHM PHARMACEUTICALS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 ▲ Rhythm Pharmaceuticals reported strong fourth quarter and full year…
- Mar 1 ▲ Rhythm Pharmaceuticals announced additional positive 52-week data fr…
- May 15 ▼ 1 insider sell $428.1K at $92.21
- Jun 22 ▼ 1 insider sell $3.7M at $100.32
- Aug 12 to Aug 13 ▼ 2 days of insider sells: $17.0M by 4 insiders, avg $116.99
- Aug 31 ▼ 1 insider sell $6.6M at $105.46
- Sep 14 ▼ 1 insider sell $5.1M at $102.67
- Oct 13 ▲ Rhythm Pharmaceuticals announced the commercial launch of IMCIVREE (…
- Oct 16 William Blair initiates
- Nov 3 Contract: Rhythm Pharmaceuticals and LG Chem Enter into Amendment to…
- Nov 3 ▲ Rhythm Pharmaceuticals reported Q3 2026 product revenue of $92.1M, w…
- Nov 3 ▲ Rhythm Pharmaceuticals reported Q3 2026 IMCIVREE revenue of $92.1M,…
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
8 insiders sold $32.9M.
- InstitutionsMIXED
Q2 2026: 29 added (2 new), 25 trimmed or exited. Largest new: Duquesne Family Office $22.6M, Assenagon Asset Management S.A $20.7M.
- AnalystsBULLISH
21 of 24 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.730 → −$3.201 over 90 days. 2 up, 9 down in 30 days.
- Short sellersSTEADY
Short interest +6.1% to 11.68M shares. 23.3 days to cover, ≈16.8% of shares.
- TrendUPTREND
11% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | ADD | $292.2M |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | $284.9M |
| FEDERATED HERMES, INC. | ADD | $198.3M |
| Capital Research Global Investors | ADD | $170.1M |
| MORGAN STANLEY | ADD | $123.5M |
| FMR LLC | TRIM | $113.9M |
| Pictet Asset Management Holding SA | ADD | $106.3M |
| NORGES BANK | DOUBLED | $76.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
24 analystsPrice is below the lowest target. Median implies +32%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | JP Morgan MAINTAIN | Overweight |
| Nov 5, 2026 | Guggenheim MAINTAIN | Buy |
| Nov 4, 2026 | Citizens MAINTAIN | Market Outperform |
| Nov 3, 2026 | Needham MAINTAIN | Buy |
| Oct 16, 2026 | William Blair INITIATE | Outperform |
| Oct 15, 2026 | JP Morgan MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Meeker David P President and CEO Sep 14, 2026 | SELL | $655.1K |
Meeker David P President and CEO Sep 14, 2026 | SELL | $3.1M |
Meeker David P President and CEO Sep 14, 2026 | SELL | $899.6K |
Meeker David P President and CEO Sep 14, 2026 | SELL | $190.0K |
Meeker David P President and CEO Sep 14, 2026 | EXERCISE | $302.5K |
Meeker David P President and CEO Sep 14, 2026 | SELL | $241.9K |
Smith Hunter C Chief Financial Officer Aug 31, 2026 | EXERCISE | $1.5M |
Smith Hunter C Chief Financial Officer Aug 31, 2026 | SELL | $1.2M |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$3.20 | -$5.71–-$0.63 | -326.0% | $108.0M |
| Next Q | -$0.69 | -$0.91–-$0.45 | +7.9% | $112.1M |
| Current FY | -$4.94 | -$7.93–-$1.25 | -59.2% | $330.6M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026| Nov 4, 2026 | Volatility Pause | Resumed |
SecBot reports
16 filings · 10 press releases · 8 bullish · 2 bearish · 1 mixed · 5 neutral- BULLISH PRESS RELEASENov 16, 2026
Rhythm Pharmaceuticals presented two-year Phase 3 TRANSCEND trial data at ObesityWeek 2026, showing sustained BMI reductions with setmelanotide in acquired hypothalamic obesity (HO). A global expert panel also established consensus diagnostic criteria for acquired HO, which could support earlier…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL INST-CLUSTERNov 4, 2026
Five institutional asset managers added to RYTM positions in Q3 2026, with aggregate net buying of…
The cluster is directionally aligned with the strong Q3 earnings beat, but the 45-day reporting lag and absence of insider buying reduce conviction. Monitor next 10-Q for any guidance revision or…
- BULLISH PRESS-RELEASENov 4, 2026
Rhythm Pharmaceuticals announced that NICE issued positive guidance expanding IMCIVREE…
Monitor for additional UK reimbursement expansions and any impact on IMCIVREE prescription trends in upcoming quarterly reports.
- BULLISH 8-KNov 3, 2026
Rhythm Pharmaceuticals reported Q3 2026 product revenue of $92.1M, well above the $84.6M…
The strong U.S. launch trajectory for IMCIVREE in acquired HO, with 29% sequential revenue growth and expanding prescriber base, supports continued top-line acceleration. The $750M term loan…
All RYTM filing & press-release reports (26)
- PRESS-RELEASE reportNov 16, 2026
- INST-CLUSTER reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- 8-K reportNov 3, 2026
- PRESS-RELEASE reportNov 3, 2026
- PRESS-RELEASE reportNov 2, 2026
- PRESS-RELEASE reportOct 13, 2026
- SC 13G reportOct 13, 2026
- 144 reportSep 14, 2026
- CLUSTER reportAug 17, 2026
- CLUSTER reportAug 17, 2026
- PRESS-RELEASE reportAug 4, 2026
- 8-K reportAug 4, 2026
- PRESS-RELEASE reportJul 8, 2026
- 144 reportJun 22, 2026
- 8-K reportJun 15, 2026
- PRESS-RELEASE reportJun 15, 2026
- PRESS-RELEASE reportJun 13, 2026
- PRESS-RELEASE reportMay 26, 2026
- PRESS-RELEASE reportMay 12, 2026
- 8-K reportMay 5, 2026
- PRESS-RELEASE reportMay 5, 2026
- PRESS-RELEASE reportMay 1, 2026
- 8-K reportApr 3, 2026
- PRESS-RELEASE reportMar 1, 2026
- 8-K reportFeb 26, 2026